Antifibrotic effects of specific targeting of the 5‐hydroxytryptamine 2B receptor (5‐HT<sub>2B</sub>R) in murine models and ex vivo models of scleroderma skin
We describe AM1476 as a highly selective inhibitor of 5-HT<sub>2B</sub>R. Treatment with AM1476 ameliorated fibrosis in three mouse models of SSc and normalized the expression of fibrosis-related genes directly in SSc skin. Because AM1476 also demonstrated good tolerability in a phase 1 trial, further clinical trials with AM1476 are currently in the planning stage.
Authors
- Helena Arozenius
- Nicholas Dickel (ORCID: https://orcid.org/0000-0002-5397-7662)
- Lars Pettersson (ORCID: https://orcid.org/0000-0001-5745-508X)
- Jörg H. W. Distler (ORCID: https://orcid.org/0000-0001-7408-9333)
- Christina Wenglén
- S. Lindgren
- Jiucun Wang (ORCID: https://orcid.org/0000-0003-2765-0620)
- Xiang Zhou
- Christoph Liebel
- Thuong Trinh‐Minh (ORCID: https://orcid.org/0009-0008-3345-3694)
- Cuong Tran Manh (ORCID: https://orcid.org/0000-0001-6630-9201)
- Andrea‐Hermina Györfi (ORCID: https://orcid.org/0000-0002-4960-3369)
- Meik Kunz (ORCID: https://orcid.org/0000-0003-0385-2084)
Institutions
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Fudan University (CN)
- Düsseldorf University Hospital (DE)
- State Key Laboratory of Genetic Engineering
- Heinrich Heine University Düsseldorf (DE)
Publication Details
- Journal
- Arthritis & Rheumatology
- Published
- 2025-03-11
- DOI
- https://doi.org/10.1002/art.43151
- Citations
- 3
- Primary Topic
- Systemic Sclerosis and Related Diseases
- Type
- article
- Field-Weighted Citation Impact
- 4.41
Funders
- Deutsche Forschungsgemeinschaft
- National Natural Science Foundation of China